JPRN-jRCT2080221155未知3 期
A clinical pharmacology study of saxagliptin in patients with type 2 diabetes mellitus
试验速览
- 阶段
- 3 期
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •Patients who meet all of the following criteria will be included:
- •1) HbA1c level equal or more than 7.0 % and less than 9.0 %
- •2) Fasting glucose level equal or more than 130 mg/dL and less than 210 mg/dL
- •3) Patients who are capable of giving informed consent
- •4) Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after completion of the study
排除标准
- •1) Patients with type 1 diabetes mellitus; patients with diabetes mellitus due to other specified drugs, mechanisms, or diseases; and patients with gestational diabetes mellitus
- •2) Patients with a medical history of diabetic coma
- •3) Patients with heart failure
- •4) Patients with a complication of active chronic hepatitis or hepatic cirrhosis
- •5) Patients undergoing treatment of glomerular diseases other than diabetic nephropathy
- •6) Patients with a history or complication of malignant tumor
研究者
相似试验
已完成
3 期
A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes MellitusDiabetesNCT01162876Kyowa Kirin Co., Ltd.20
进行中（未招募）
不适用
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With Type 2 diabetes mellitus (T2DM)MedDRA version: 17.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2014-003964-18-Outside-EU/EEABristol-Myers Squibb Company12
已完成
1 期
A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-AdministrationType 2 Diabetes Mellitus(T2DM)NCT01755494AstraZeneca64
终止
1 期
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DMType 2 Diabetes MellitusNCT01525225AstraZeneca4
进行中（未招募）
1 期
Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects with Type 2 Diabetes Mellitus on Previous Metformin TreatmentEUCTR2014-003788-39-DEProfil Mainz GmbH & Co KG